BofA analyst Allen Lutz downgraded Omnicell (OMCL) to Neutral from Buy with a price target of $57, up from $44. The market is pricing in a clear return to growth for Omnicell’s Product business with shares up 30%, notes the analyst. However, while product extensions like XTAmplify can help drive incremental sales, visibility into growth is low, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMCL: